Methods of intravenous administration of glyburide
The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.
1. A method of treating a sulfonylurea-responsive condition in a patient in need of said treatment, comprising administering to the patient in a manner to achieve a clinically-effective level of a glyburide drug,
a) a first dose of said glyburide drug during a first period of time;
b) a second dose of said glyburide drug during a second period of time; and
c) a third dose of said glyburide drug during a third period of time;
wherein said second dose delivers to the patient less of said glyburide drug per unit of time than said first dose, and said third dose delivers to the patient less of said glyburide drug per unit of time than said second dose.
2. The method of claim 1 , wherein each of the second and third doses are independently administered at a rate of about 15 μg/hr to about 300 μg/hr.
3. The method of claim 2 , wherein the first dose delivers about 125 μg to about 150 μg of said glyburide drug.
4. The method of claim 1 , wherein the total amount of said glyburide drug administered is about 6 mg per day or less.
5. The method of claim 4 , wherein the total amount of said glyburide drug administered is about 3.5 mg per day or less.
6. The method of claim 5 , wherein the total amount of said glyburide drug administered is about 3 mg per day or less.
7. The method of claim 1 , wherein the first dose delivers about 125 μg to about 150 μg of said glyburide drug.
8. The method of claim 7 , wherein said second dose is administered over about 1 hour to about 10 hours.
9. The method of claim 8 , wherein said first dose is administered over about 3 minutes or less.
10. The method of claim 1 wherein said second dose delivers about 150 μg/hr to about 175 μg/hr of said glyburide drug for a period of time of about 6 hours.
11. The method of claim 10 , wherein said third dose delivers of about 100 μg/hr to about 125 μg/hr of said glyburide drug.
12. The method of claim 11 , wherein third dose is administered over a period of time of about 66 hours, whereby the sum of the periods of time of the first continuous infusion and of the second continuous infusion total about 72 hours.
13. The method of claim 12 , wherein said first dose comprises administration of about 130 μg of said glyburide drug followed by a second dose of about 163 μg/hr said glyburide drug for 6 hours followed by third dose of about 112 μg/hr said glyburide drug for 66 hours.
14. The method of claim 1 , wherein the sulfonylurea-responsive condition is selected from the group consisting of acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, and hypoxia/ischemia.
15. A method of treating a sulfonylurea-responsive condition in a patient in need of said treatment, comprising administering to the patient in a manner to achieve a substantially steady-state level of a glyburide drug,
a) a first dose of said glyburide drug during a first period of time;
b) a second dose of said glyburide drug during a second period of time; and
c) a third dose of said glyburide drug during a third period of time;
wherein said second dose delivers to the patient less of said glyburide drug per unit of time than said first dose, and said third dose delivers to the patient less of said glyburide drug per unit of time than said second dose.
16. The method of claim 15 , wherein sulfonylurea-responsive condition is selected from the group consisting of acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, and hypoxia/ischemia.
17. The method of claim 16 , wherein said first dose is administered over about 3 minutes or less, said second dose delivers about 150 μg/hr to about 175 μg/hr of said glyburide drug for a period of time of about 6 hours, and said third dose delivers of about 100 μg/hr to about 125 μg/hr of said glyburide drug.